Comment on Share Price Movement

RNS Number : 6817Q
MyHealthChecked PLC
01 March 2021
 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED.  ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

("MyHealthChecked" or the "Company")

 

Comment on Share Price movement

 

MyHealthChecked Plc (AIM: MHC), the personalised healthcare company, notes the increase in its share price this morning, and ha s become aware of speculation over the weekend that a significant potential contract is in the pipeline.

 

As previously notified on 29 December 2020, the Company's COVID-19 testing service has been added to the UK Government's approved COVID-19 private testing providers list for General Testing, and the Test to Release for International Travel scheme introduced on 15 December 2020.

 

Whilst the Company is engaged in commercial discussions with a number of parties for the supply of COVID-19 testing kits, no contracts have been signed to date, nor is there any certainty that any of these discussions will result in commercial agreement.

 

As required by the AIM Rules for Companies, the Company will make further notifications as required.

 

MyHealthChecked plc

www.myhealthchecked.com

P enny McCormick , Chief Executive Officer

via Walbrook PR

Maddy Kennedy, Chief Financial Officer




SPARK Advisory Partners Limited (NOMAD)

Tel: +44 (0)20 3368 3550

Neil Baldwin




Oberon Capital Ltd (Broker)

Tel: +44 (0)203 179 5344

Mike Seabrook

mikeseabrook@oberoninvestments.com



Walbrook PR Ltd (Media & Investor Relations)

Tel: +44 (0)20 7933 8780 or concepta@walbrookpr.com

Paul McManus

Mob: +44(0)7980 541 893

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
SPMJBMLTMTAMMLB
UK 100

Latest directors dealings